This page shows you your search results in order of relevance. This is page number 13.

Order by Relevance | Date

Total 4441299 results found since Jan 2013.

Impact of environmental factors and physical activity on disability and quality of life in CIDP
This study adds evidence to the possible role of physical activity in improving symptom severity, disability and QoL in patients with CIDP. None of the other environmental factors investigated appeared to have an impact on the severity and health perception of CIDP.
Source: Journal of Neurology - May 18, 2020 Category: Neurology Source Type: research

A case of CIDP concurrent with MGUS IgG kappa responsive to autologous stem cell transplantation
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired immune-mediated disease of the peripheral nervous system, either being isolated or associated with other systemic diseases, most frequently with lymphoproliferative subtypes.1 CIDP concurrent with monoclonal gammopathy of undetermined significance (MGUS) accounts for up to 20%–30% of all cases,2 is often considered clinically indistinguishable from typical CIDP, and responds similarly to immunologic therapies.3 CIDP clinical course may be poorly responsive to conventional immunologic or chemotherapy treatment.4 Consequently, allogeneic an...
Source: Neurology Neuroimmunology and Neuroinflammation - September 14, 2020 Category: Neurology Authors: Colucci, G., Pabst, T., Bacher, U., Maggioli, C., Zecca, C., Gobbi, C. Tags: Chronic inflammatory demyelinating polyneuropathy Clinical/Scientific Notes Source Type: research

Serum Contactin-1 in CIDP: A Cross-Sectional Study
Conclusions These findings suggest that serum contactin-1 levels have the potential to serve as a possible diagnostic biomarker of paranodal injury in CIDP. Classification of Evidence This study provides class II evidence that serum contactin-1 levels can discriminate between patients with CIDP with or without paranodal antibodies with a sensitivity of 71% (95% CI: 56%–85%) and a specificity of 97% (95% CI: 83%–100%).
Source: Neurology Neuroimmunology and Neuroinflammation - July 20, 2021 Category: Neurology Authors: Wieske, L., Martin-Aguilar, L., Fehmi, J., Lleixa, C., Koel-Simmelink, M. J. A., Chatterjee, M., van Lierop, Z., Killestein, J., Verhamme, C., Querol, L., Rinaldi, S., Teunissen, C. E., Eftimov, F. Tags: Chronic inflammatory demyelinating polyneuropathy Article Source Type: research

Autoantibodies against contactin ‐associated protein‐1 and complexes of paranode‐specific proteins in chronic inflammatory demyelinating polyradiculoneuropathy
ConclusionsThis is the first confirmed Japanese case of anti-Caspr1 antibody-positive CIDP with a clinical signature similar to that of patients of western origins. Our preliminary study did not identify the presence of specific antibodies against the paranode protein complexes, and the primary target antigen is likely Caspr1.
Source: Clinical and Experimental Neuroimmunology - October 27, 2022 Category: Neurology Authors: Michiaki Koga, Toshihiko Maeda, Fumitaka Shimizu, Takashi Kanda Tags: ORIGINAL ARTICLE Source Type: research

Autoantibodies against contactin ‐associated protein 1 and complexes of paranode‐specific proteins in chronic inflammatory demyelinating polyradiculoneuropathy
ConclusionsThis is the first confirmed Japanese case of anti-Caspr1 antibody-positive CIDP with a clinical signature similar to that of patients of Western origin. Our preliminary study did not identify the presence of specific antibodies against the paranode protein complexes, and the primary target antigen is likely Caspr1.
Source: Clinical and Experimental Neuroimmunology - November 12, 2022 Category: Neurology Authors: Michiaki Koga, Toshihiko Maeda, Fumitaka Shimizu, Takashi Kanda Tags: ORIGINAL ARTICLE Source Type: research

Impairment and Disability in 20 CIDP Patients According to Disease Activity Status (PD1.006)
CONCLUSIONS: The evaluated scores outline 2 major clinically useful groups: 1) sensory scores (ISS, sensory component of NDS) and 2) disability and motor scores. The most useful scores appear the ones evaluating the disability, R-ODS topping the list, correlating both with motor disability and the disease activity. In contrast, the sensory score does not seem to fully evaluate the disease severity in the studied cohort.Disclosure: Dr. Kuntzer has received personal compensation for activities with Pfizer. Dr. Kuntzer has received research support from CSL Behring. Dr. Panaite has nothing to disclose. Dr. Renaud has nothing ...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Kuntzer, T., Panaite, A., Renaud, S., Steck, A. Tags: PD1 Peripheral Nerve Source Type: research

Impairment and disability in 20 CIDP patients according to disease activity status
Abstract Twenty patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) meeting the EFNS/PNS criteria were examined in order to assess differences/similarities between the various grading systems according to CIDP disease activity status (CDAS). A Principal Component (PC) analysis and the correlations between the following scores were performed: Neurological Symptom Score; MRC sum score; Neurological Impairment Score; Hammersmith Functional Motor Scale; Inflammatory Neuropathy Cause and Treatment (INCAT) Sensory Sum Score; Overall Disability Sum Score; INCAT Disability Score; Rasch‐built Overall Di...
Source: Journal of the Peripheral Nervous System - August 5, 2013 Category: Neurology Authors: Petrica‐Adrian Panaite, Susanne Renaud, Rudolf Kraftsik, Andreas J. Steck, Thierry Kuntzer Tags: Research Report Source Type: research

Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy (CIDP)
Conclusions: In our patient population, the EFNS and Neuropathy Association criteria stand out due to high sensitivity and specificity. © 2013 Wiley Periodicals, Inc.
Source: Muscle and Nerve - October 6, 2013 Category: Internal Medicine Authors: Ari Breiner, Thomas H. Brannagan Tags: Research Article Source Type: research

Nerve Size in CIDP Varies with Disease Activity and Therapy Response Over Time: A Retrospective Ultrasound Study
Conclusion: In CIDP, enlarged nerves normalized or decreased with remission. © 2014 Wiley Periodicals, Inc.
Source: Muscle and Nerve - February 25, 2014 Category: Internal Medicine Authors: Craig M. Zaidman, Alan Pestronk Tags: Research Article Source Type: research

Can Follow-up Electrodiagnostic Studies in Patients with CIDP That Improved Following IGIV-C Treatment Predict Relapse after Treatment Discontinuation? (P4.106)
CONCLUSIONS: An increased total number of demyelinating findings in CIDP patients with clinical improvement following IGIV-C treatment may indicate a higher risk of clinical relapse following treatment cessation. Demyelinating EDX abnormalities can fluctuate while on treatment, possibly indicating some level of continuing disease activity. Certain EDX measures may be more predictive of relapse than others.Disclosure: Dr. Chin has received personal compensation for activities with Grifols Bioscience as a consultant. Dr. Deng has received personal compensation for activities with Talecris Biotherapeutics. Dr. Bril has receiv...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Chin, R., Deng, C., Bril, V., Latov, N., Hartung, H., Merkies, I., Donofrio, P., Van Doorn, P., Dalakas, M. Tags: Neuromuscular: Electrodiagnostic Source Type: research

Treatment Of Experimental CIDP Using Lentivirus Transduced Dendritic Cells Expressing VIP (S6.006)
Conclusion: This proof of principle study suggests that the use of LV-VIP-DCs would be applicable to progressive cases of CIDP refractory to standard immunosuppressive therapy including agents like glucocorticoids, rituximab, and intravenous immunoglobulin.Study Supported by: GBS-CIDP Foundation International and Mehmet Yalvac is a Paul D. Wellstone Muscular Dystrophy Cooperative Research Center Postdoctoral FellowDisclosure: Dr. Yalvac has nothing to disclose. Dr. Arnold has nothing to disclose. Dr. Hussain has nothing to disclose. Dr. Braganza has nothing to disclose. Dr. Clark has nothing to disclose. Dr. Ubogu has noth...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Yalvac, M., Arnold, W., Hussain, S.-R., Braganza, C., Clark, K. R., Ubogu, E., Mendell, J., Sahenk, Z. Tags: Neuromuscular Disease: Gene Therapy Source Type: research

Treatment Of Experimental CIDP Using Lentivirus Transduced Dendritic Cells Expressing VIP (I6-2.005)
Conclusion: This proof of principle study suggests that the use of LV-VIP-DCs would be applicable to progressive cases of CIDP refractory to standard immunosuppressive therapy including agents like glucocorticoids, rituximab, and intravenous immunoglobulin.Study Supported by: GBS-CIDP Foundation International and Mehmet Yalvac is a Paul D. Wellstone Muscular Dystrophy Cooperative Research Center Postdoctoral FellowDisclosure: Dr. Yalvac has nothing to disclose. Dr. Arnold has nothing to disclose. Dr. Hussain has nothing to disclose. Dr. Braganza has nothing to disclose. Dr. Clark has nothing to disclose. Dr. Ubogu has noth...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Yalvac, M., Arnold, W., Hussain, S.-R., Braganza, C., Clark, K. R., Ubogu, E., Mendell, J., Sahenk, Z. Tags: Peripheral Neuropathies Data Blitz Presentations Source Type: research

Cidp Variants in Diabetes: Measuring Treatment Response with A Small Nerve Fiber Test
We present a case of a patient with type 2 diabetes (T2D) and CIDP whose treatment response was measurable with the Sudoscan sudomotor function test. This test may represent a new objective evaluation of the treatment of CIDP.
Source: Journal of Diabetes and Its Complications - November 6, 2014 Category: Endocrinology Authors: Marie-Laure Névoret, Aaron I. Vinik Source Type: research

Subcutaneous immunoglobulin in CIDP and MMN: a short-term nationwide study
Abstract This multi-center Italian prospective observational study reports the 4 months follow-up data of 87 patients affected by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN) shifted from intravenous to subcutaneous immunoglobulin treatment. A therapeutic shift from intravenous to subcutaneous immunoglobulin was performed in 87 patients (66 CIDP; 21 MMN) affected by immune-mediated peripheral neuropathies with evidence of a sustained clinical response to intravenous immunoglobulin. Patients were evaluated by means of the Overall Neuropathy Limitation Scal...
Source: Journal of Neurology - November 1, 2014 Category: Neurology Source Type: research

Long‐term plasma exchange in pediatric CIDP
We report on a 16‐year‐old boy with renal insufficiency undergoing hemodialysis who developed CIDP and underwent TPE with dramatic long‐term response to therapy. Nerve ultrasound and MRI findings are also reported. In our patient TPE was chosen because he was already undergoing hemodialysis. Though it is not considered a first‐line therapy in pediatric CIDP, TPE may be a good therapeutic choice also in long‐term period. J. Clin. Apheresis, 2015. © 2015 Wiley Periodicals, Inc.
Source: Journal of Clinical Apheresis - February 7, 2015 Category: Hematology Authors: Marta Lucchetta, Enrico Vidal, Stefano Sartori, Marta Campagnolo, Chiara Dalla Torre, Piero Marson, Renzo Manara, Chiara Briani Tags: Brief Report Source Type: research